Predictors of post-treatment relapse to smoking in successful quitters: pooled data from two phase III varenicline trials.

ABSTRACT:

Background

Identifying predictors of smoking relapse helps to elucidate the challenges of long-term smoking cessation and provides direction for improved treatment development.

Methods

In this post hoc data analysis, we examined predictors of relapse from end-of-treatment (week 13) through 1-year follow-up (week 52) for treatment-responding participants who achieved the primary efficacy endpoint of 4-week continuous abstinence (weeks 9-12), during two phase III varenicline trials.

Results

Of 626 smokers classified as treatment responders for all treatment groups across both trials, 301 (48%) relapsed during follow-up (weeks 13-52). The odds of relapsing were almost 5 times greater (odds ratio [OR]=4.92, 95% confidence interval [CI]: 2.77-8.97; p<.001) for treatment re

SUBMITTER: Heffner JL 

PROVIDER: S-EPMC2875368 | biostudies-literature | 2010 Jun

REPOSITORIES: biostudies-literature